99 related articles for article (PubMed ID: 19383920)
1. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan.
Zeng J; Cai S; Yi Y; He Y; Wang Z; Jiang G; Li X; Du J
Cancer Res; 2009 May; 69(9):3963-70. PubMed ID: 19383920
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
[TBL] [Abstract][Full Text] [Related]
3. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model.
Lim JY; Lee SE; Park G; Choi EY; Min CK
Exp Hematol; 2014 Oct; 42(10):862-6.e3. PubMed ID: 24971697
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.
Friberg M; Jennings R; Alsarraj M; Dessureault S; Cantor A; Extermann M; Mellor AL; Munn DH; Antonia SJ
Int J Cancer; 2002 Sep; 101(2):151-5. PubMed ID: 12209992
[TBL] [Abstract][Full Text] [Related]
6. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Nakamura N; Hara T; Shimizu M; Mabuchi R; Nagano J; Ohno T; Kochi T; Kubota M; Shirakami Y; Goto N; Ito H; Saito K; Tanaka T; Moriwaki H; Tsurumi H
Int J Hematol; 2015 Sep; 102(3):327-34. PubMed ID: 26243621
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
9. The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors.
Moreno ACR; Porchia BFMM; Pagni RL; Souza PDC; Pegoraro R; Rodrigues KB; Barros TB; Aps LRMM; de Araújo EF; Calich VLG; Ferreira LCS
Front Immunol; 2018; 9():1914. PubMed ID: 30186285
[TBL] [Abstract][Full Text] [Related]
10. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
11. Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,3-dioxygenase axis.
Xiao BG; Liu X; Link H
Steroids; 2004 Sep; 69(10):653-9. PubMed ID: 15465110
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation.
Chen X; Liu L; Yang P; Wu C; Jin H; Xing L; Li B; Zhou H; Huang X; Zhu L
Immunol Lett; 2006 Nov; 107(2):140-7. PubMed ID: 17055065
[TBL] [Abstract][Full Text] [Related]
14. A new tumor vaccine: FAPτ-MT elicits effective antitumor response by targeting indolamine2,3-dioxygenase in antigen presenting cells.
Yi YM; Zhang G; Zeng J; Huang SC; Li LL; Fang R; Jiang GM; Bu XZ; Cai SH; Du J
Cancer Biol Ther; 2011 May; 11(10):866-73. PubMed ID: 21372637
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of increased indoleamine 2,3-dioxygenase activity attenuates Toxoplasma gondii replication in the lung during acute infection.
Murakami Y; Hoshi M; Hara A; Takemura M; Arioka Y; Yamamoto Y; Matsunami H; Funato T; Seishima M; Saito K
Cytokine; 2012 Aug; 59(2):245-51. PubMed ID: 22609210
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
19. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
